Forum

Jennifer Carroll

Good Morning @Constance
PAAB would need additional information to make the assessment of the claim proposed above. There are many considerations outside of just the source such as, does it suggest equivalence between products on a per unit basis and what is the intent of the per unit comparison. Given these unknowns, it is difficult to provide a definitive answer in a general space. We suggest submitting the copy for review.

Constance

hi Paab!

I would like to develop an APS to highlight all of the Rx products we have in our portfolio (all with the same indication). Provided I can find a compared prices must come from a single independent source (as described in question 438), would I be able to present the price as a unit cost? For example, the price of injectable pen X is $450 for 450 units, i.e. $1/unit.

Jennifer Carroll

Hey @GMC
This copy would be reviewed in the context of the entirety of the piece. The context of the message “dispensed as written” will matter. See also the PAAB advisory on Advertising messages referring to "no sub".

Jennifer Carroll

Hey @mhouzer

The difference between the Standard 4-day initial review of RMTs and submitting as an ARO-4 is that the subsequent revision turnaround time will be an expedited 2-days rather than the standard 3-days. If you anticipate needing a few rounds of back and forth, this can be a good option to get to your final letter more quickly.

Jennifer Carroll

AI MODEL - Phase I Testing Opt-In Deadline!

@Manufacturer the Pharmaceutical Advertising Advisory Board (PAAB) is taking a significant step forward in innovation by launching the first phase of testing of our ground-breaking AI model on live files starting May 1st.

On April 1st, in preparation for launch, we sent an eblast to industry announcing the deadline for full opt-in was now set for May 1st. Manufacturers who opt-in after the May 1st deadline will likely need to wait until a sufficient number of additional opt-ins are accumulated. This grouping of late opt-ins is intended to support cost-effectiveness.

This initiative marks a major milestone in enhancing the efficiency, consistency, and effectiveness of advertising review processes for our industry. Ensuring that preclearance keeps pace with the speed and quantity of specialization afforded through AI adoption across the industry.

If you have not yet reached out to PAAB and want to be among the first to experience the benefits of this exciting new project, please contact info@paab.ca today.

@Agency we'll be reaching out shortly for your collaboration on the AI driven augmentation of the submission process.

Cheers
PAAAB

Jennifer Carroll

Good Morning @HollyMed

Pooled data is not acceptable even if part of a pre-planned long-term extension study.

Jennifer Carroll

Good Morning @Supriya

We assume that you are referring to a patient targeted APS. As a patient would not have a prescription for all the products, this would contravene the direct-to-consumer advertising (DTCA) regulations (Section C.01.044 of the Food and Drugs Act Regulations) to create a link to the therapeutic use (i.e. indication could not be included) for products they are not prescribed. While the three base levels of fair balance apply only to HCP-targeted APS, a weblink to the Terms of Market Authorization (TMA) links the therapeutic use, a violation of the DTCA regulations.

Jennifer Carroll

What did we learn from you in 2024?

In October, PAAB sent out our Client Survey to better understand your experience with us — what’s working, what’s not, and where we can grow together.

This year’s survey offered deeper insights into awareness of recent Code and guidance updates, and helped us identify how we can better support your PAAB experience moving forward.

Thank you to everyone who participated. Your feedback is already driving improvements across training, review practices, and communication.

Check out the full Customer Insights Report

Forum

Remote Workshop 2020 series

Posts

Member List